1. Home
  2. IXHL vs ALXO Comparison

IXHL vs ALXO Comparison

Compare IXHL & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Incannex Healthcare Inc.

IXHL

Incannex Healthcare Inc.

HOLD

Current Price

$3.92

Market Cap

97.6M

Sector

N/A

ML Signal

HOLD

Logo ALX Oncology Holdings Inc.

ALXO

ALX Oncology Holdings Inc.

HOLD

Current Price

$2.18

Market Cap

68.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IXHL
ALXO
Founded
2001
2015
Country
Australia
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
97.6M
68.3M
IPO Year
2024
2020

Fundamental Metrics

Financial Performance
Metric
IXHL
ALXO
Price
$3.92
$2.18
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$3.42
AVG Volume (30 Days)
6.3M
1.0M
Earning Date
01-01-0001
06-01-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
31.02
EPS
N/A
N/A
Revenue
$12,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.11
$0.41
52 Week High
$5.17
$2.66

Technical Indicators

Market Signals
Indicator
IXHL
ALXO
Relative Strength Index (RSI) 89.14 52.41
Support Level $0.32 $1.41
Resistance Level N/A $2.27
Average True Range (ATR) 0.13 0.27
MACD 0.39 -0.05
Stochastic Oscillator 76.27 23.08

Price Performance

Historical Comparison
IXHL
ALXO

About IXHL Incannex Healthcare Inc.

Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.

About ALXO ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

Share on Social Networks: